Risk Partners Life Sciences Roundtable 2024, thank you very much! Already for the 26.06.2025 >

Atrialis GmbH - experts in clinical trial insurance &
Risk Partners will play in the same team in future.

LifeSciences - Leading risk concepts for leading science! 

This has been our guiding principle for many years in advising innovative companies in the fields of biotechnology, pharmaceuticals and medical products on risk issues and providing them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insurance of a clinical trial).

Together with my team at Risk Partners GmbH, we want to emphasize our focus, passion and expertise in insurance for the life sciences industry and support even more medical research initiatives with special insurance concepts for clinical trials and subject coverage. The same applies to our colleagues at Atrialis GmbH: experts in clinical trials, which has been one of the leading companies in the life sciences sector since 2007.

In order to be able to offer our joint target customers an even better service and range of products, we have notarized the merger of our companies and look forward to jointly providing market-leading service and risk transfer to life science customers in the future. From the foundation to the NASDAQ IPO - accompanied by life sciences insurance specialists.

Also read our other blog posts

Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
Your question has not been answered?
We will be happy to advise you in a free initial consultation.